Developing Stem Cell Therapy for Type 1 Diabetes Mellitus
Diabetes/Metabolism Research and Reviews · 2025
DOI: 10.1002/dmrr.70079 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2025. Verfasst von Riccardo Calafiore. Beteiligte Einrichtung: Diabetes Research Foundation ETS (DRF), Laboratory for Endocrine Cell Transplants, University of Perugia, Perugia, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
The restricted availability of cadaveric isolated human donor islets sharply limits progress in clinical trials of islet cell transplantation. Furthermore, the host's general pharmacologic immunosuppression is invariably needed to grant survival and function of the human islet grafts. The former mandates validation of new sources of insulin producing cells. The latter requires new strategies to circumvent use of general immunosuppressive agents. A possible solution to these problems could consist using of human stem cells, whose availability is indefinite, that are suitable for both, differentiation into endocrine cell phenotypes, and genetic manipulations to alter immunogenicity. Pluripotent human stem cells, either embryonic (ESCs), derived from the blastocyst, or those originating from adult somatic cells, artificially induced to pluripotency (iPSCs), or finally, multipotent human adult mesenchymal stem cells (MSCs) may be considered. MSCs are more difficult to trans‐differentiate into Beta‐like cells, but they hold powerful immunoregulatory properties, and do not pose ethical problems. Both ESCs and iPSCs show pro's and con's, in terms of ethical acceptance (ESCs), and technical feasibility (iPSCs), with the pending immune problems, that might be attenuated by gene editing manoeuvres to render the cells ‘immune evasive’. Early pilot clinical trials with either ESCs or iPSCs in immunosuppressed T1D patients showed that hyperglycemia can be reversed, although challenges remain.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Diabetes Research Foundation ETS (DRF), Laboratory for Endocrine Cell Transplants, University of Perugia, Perugia, Italy.
- UniCamillus-Saint Camillus International University of Health Sciences, Rome, Italy.
ORCID-Profile: Riccardo Calafiore
Zitieren
APA
Calafiore, R. (2025). Developing Stem Cell Therapy for Type 1 Diabetes Mellitus. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70079
Vancouver
Calafiore R. Developing Stem Cell Therapy for Type 1 Diabetes Mellitus. Diabetes/Metabolism Research and Reviews. 2025. doi:10.1002/dmrr.70079
BibTeX
@article{Calafiore2025,
author = {Calafiore, Riccardo},
title = {Developing Stem Cell Therapy for Type 1 Diabetes Mellitus},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
doi = {10.1002/dmrr.70079}
}
EUVIMED